Articles

New developments in drug-eluting stents, such as biodegradable materials and bifurcated stents, are expected to prompt an increase in market value. Companies like Biosensors and Abbott are...

September 8, 2011 – Patients at a high risk for a second stroke who received intensive medical treatment had fewer strokes and deaths than patients who received a brain stent in addition to the...

A drug-eluting, self-expanding stent that does not use a drug-carrier polymer is before the U.S. Food and Drug Administration (FDA) final pre-market approval (PMA) review and a decision is...

Navigating through the world of coronary stents is about to become more complex.  A plethora of new products are on the horizon, which will utilize new platforms and alloys and present novel...

Carotid stenting is a more complex and challenging procedure than coronaries or peripheral vessels. Carotid stenting experts have the following advice for hospitals and physicians that want to...

In a move that will likely have a significant impact on how many patients are treated for carotid artery disease, the U.S. Food and Drug Administration (FDA) in May cleared the use of a stent to...

In a move that will likely have a significant impact how many patients are treated for carotid artery disease, the U.S. Food and Drug Administration (FDA) has cleared the use of a stent to treat...

April 9, 2011 - The Resolute zotarolimus-eluting stent using a new biocompatible polymer achieved a lower rate of restenosis and in-stent thrombosis compared to the Endeavor stent at 12 months in...

April 8, 2011 – In the largest randomized, multicenter trial to compare drug-eluting stents (DES) and bare-metal stents (BMS) placed in saphenous vein graft lesions, researchers found that DES led...

April 8, 2011 — A study from a South Korean research team found that angioplasty with a sirolimus-eluting stent was non-inferior to coronary artery bypass surgery (CABG) in patients with...